A randomized, Double-Blind, Phase III Comparative Trial of Two Doses of ZD 1839 in Combination with Paclitaxel and Carboplatin Versus Placebo in Combination with Paclitaxel and Carboplatin in Chemotherapy Patient with Advanced Non-Small Cell Lung Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/009/30/04

Funding

  • AstraZeneca: $31,620.00